Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

European Journal of Cancer

Volumn 46, Issue 5, 2010, Pages 901-911

  van Cruijsen, Hester ^a   Voest, Emile E ^b   Punt, Cornelis J A ^c   Hoekman, Klaas ^a   Witteveen, Petronella O ^b   Meijerink, Martijn R ^a   Puchalski, Thomas A ^d   Robertson, Jane ^d   Saunders, Owain ^d   Jürgensmeier, Juliane M ^d   van Herpen, Carla M L ^c   Giaccone, Giuseppe ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Angiogenesis inhibitors; Clinical trial; EGFR; Phase I; VEGFR 1; VEGFR 2; VEGFR 3

Indexed keywords

CEDIRANIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; DYSPHONIA; DYSPNEA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALAISE; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SKIN PRURITUS; SOLID TUMOR; WEIGHT REDUCTION;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIARRHEA; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NETHERLANDS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77349095970     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.12.023     Document Type: Article

References (42)

1. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 (2004) 581-611
2. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 (1995) 183-232
3. Brabender J., Danenberg K.D., Metzger R., et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7 (2001) 1850-1855
4. van Cruijsen H., Giaccone G., and Hoekman K. Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int J Cancer 117 (2005) 883-888
5. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
6. Jung Y.D., Mansfield P.F., Akagi M., et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 38 (2002) 1133-1140
7. Shaheen R.M., Ahmad S.A., Liu W., et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Brit J Cancer 85 (2001) 584-589
8. Herbst R.S., O'Neill V.J., Fehrenbacher L., et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25 (2007) 4743-4750
9. Wedge S.R., Kendrew J., Hennequin L.F., et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65 (2005) 4389-4400
10. Drevs J., Siegert P., Medinger M., et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25 (2007) 3045-3054
11. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
12. Karkkainen M.J., Haiko P., Sainio K., et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 5 (2004) 74-80
13. Tammela T., Zarkada G., Wallgard E., et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454 (2008) 656-660
14. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19 (2001) 843-850
15. Kim E.S., Hirsh V., Mok T., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372 (2008) 1809-1818
16. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
17. Voest EE, van Cruijsen H, van Herpen CML, et al. Evaluation of thyroid function in an open-label Phase I study of AZD2171 with gefitinib. Eur J Cancer 2007;5(Suppl) [abst 705].
18. Baselga J., Rischin D., Ranson M., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20 (2002) 4292-4302
19. Ranson M., Hammond L.A., Ferry D., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20 (2002) 2240-2250
20. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
21. Veronese M.L., Mosenkis A., Flaherty K.T., et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24 (2006) 1363-1369
22. Holden S.N., Eckhardt S.G., Basser R., et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16 (2005) 1391-1397
23. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New Engl J Med 349 (2003) 427-434
24. Cobleigh M.A., Langmuir V.K., Sledge G.W., et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30 (2003) 117-124
25. Perez-Soler R., Chachoua A., Hammond L.A., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22 (2004) 3238-3247
26. Gelderblom H, Verweij J, Steeghs N, et al. Phase I, safety, pharmacokinetic and biomarker study of BAY 57-9352, an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors. J Clin Oncol 2006;24(S18) [abst 3040].
27. Schoeffski P, Wolter P, Himpe U, et al. Sunitinib-related thyroid dysfunction: a single-center retrospective and prospective evaluation. J Clin Oncol 2006;24(18S) [abst 3092].
28. Shaheen PE, Tamaskar IR, Salas RN, et al. Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. J Clin Oncol 2006;24(18S) [abst 4605].
29. Desai J, Dileo P, Morgan JA, et al. Hypothyroidism may accompany SU11248 therapy in a subset of patients (pts) with metastatic (met) gastrointestinal stromal tumors (GIST) and is manageable with replacement therapy. J Clin Oncol 2005;23(16S) [abst 3040].
30. Desai J., Yassa L., Marqusee E., et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145 (2006) 660-664
31. Adjei A.A., Molina J.R., Mandrekar S.J., et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 13 (2007) 2684-2691
32. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 356 (2007) 125-134
33. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med 356 (2007) 115-124
34. Motzer R.J., Amato R., Todd M., et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21 (2003) 99-101
35. Dawson N.A., Guo C., Zak R., et al. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 10 (2004) 7812-7819
36. Jermann M., Stahel R.A., Salzberg M., et al. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol 57 (2006) 533-539
37. Sridhar SS, Mackenzie MJ, Hotte SJ, et al. Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium. J Clin Oncol 2008;26(15S) [abst 5047].
38. Drevs J., Zirrgiebel U., Schmidt-Gersbach C.I., et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16 (2005) 558-565
39. Ebos J.M., Lee C.R., Christensen J.G., Mutsaers A.J., and Kerbel R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104 (2007) 17069-17074
40. Meijerink M.R., van Cruijsen H., Hoekman K., et al. The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol 17 (2007) 1700-1713
41. Bukowski R.M., Kabbinavar F.F., Figlin R.A., et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25 (2007) 4536-4541
42. Hainsworth J., and Herbst R.S. A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin) in combination with erlotinib (Tarceva) compared with erlotinib alone for treatment of advanced non-small-cell lung cancer after failure of standard first-line therapy (BETA). J Thorac Oncol 3 (2008) S302